CDC Drug Service Diphtheria Antitoxin (DAT) Treatment And Adverse Effects

	•		, ,		
P	Patient ID	Name			
Drug			Date of Request Month Day Year		
Diphtheria Antitoxin is currently not licensed in the United States. The National Immunization Program of the Centers for Disease Control and Prevention (CDC) is the national center for consultation of suspected diphtheria cases and is responsible for providing diphtheria antitoxin for therapy. CDC has received approval to distribute this product to physicians as an Investigational New Drug (IND) in accordance with requirements of the Food and Drug Administration (FDA). Under the provisions of our IND protocol we must obtain clinical information on each patient who has received DAT. Please complete and return this form at the time of hospital discharge for each patient receiving antitoxin. Please FAX form to: CDC Drug Service at (404) 639-3717 or mail form to: CDC Drug Service, Mailstop D09, Centers for Disease Control and Prevention, 1600 Clifton Road. Atlanta. Georgia 30333.					
LECTING	Was Sensitivity Testing Do Antitoxin Administration? Y = Yes N = No	one Prior to	If Yes, at What Site?	Other Other	
THOUSE IN THE	What Dosage And Diluent	?	Result		
ALLI CALIN ADMINI	Antitoxin Given by Intravenous (IV) or Intramuscular (IM) Injection Dates DAT Given Time DAT Given Route Vials Given Lot Number V=IV M=IM M=IM				
AINTITIONIN INEACTIONS	Reaction General: Fever Chills Urticaria Swelling/Edema Anaphylaxis Serum Sickness	If Yes, How After DAT G	Long	of Urticaria Effects. Reaction	Is For All Adverse Effects, Including Location a, Rash, Swelling, or Other Localized Adverse Treatment Given For an Adverse Effect? If Yes,
	Rash: Macular/Papular Vesicular Other Other Hypersensitivity Other Reaction				oxin Administration Stopped Due to an ffect? If Yes, Describe.

This document can be found on the CDC website at: http://www.cdc.gov/vaccines/vpd-vac/diphtheria/dat/downloads/diph_ae_rpt.pdf